Exploring schizophrenia drug-gene interactions through molecular network and pathway modeling

Area of Science:

• Pharmacogenomics
• Neuroscience
• Computational Biology

Background:

• Schizophrenia treatment involves antipsychotic drugs targeting various genes.
• Understanding complex drug-gene interactions is crucial for personalized medicine.
• Existing research lacks a systematic analysis of antipsychotic drug-gene networks in schizophrenia.

Purpose of the Study:

• To construct and analyze a comprehensive drug-target gene network for schizophrenia.
• To identify key pathways and bridge genes involved in antipsychotic drug action.
• To investigate the unique interaction profile of Haloperidol in schizophrenia treatment.

Main Methods:

• Retrieved 39 schizophrenia-related antipsychotic drugs and 142 associated targets from DrugBank.
• Constructed a drug-target gene network, identifying overrepresented pathways (e.g., neuroactive ligand-receptor, glutamate, glycine metabolism).
• Integrated pathway information to reveal bridge genes (e.g., GRIN2A, DRD1, DRD2) connecting network sub-modules.

Main Results:

• Identified 142 drug-targeted genes significantly enriched in neuroactive ligand-receptor, glutamate, and glycine metabolism pathways.
• Discovered crucial bridge genes including GRIN2A, GRIN3B, GRIN2C, GRIN2B, DRD1, and DRD2, encoding NMDA and dopamine receptors.
• Haloperidol was the sole drug directly interacting with these identified pathways and receptors.

Conclusions:

• The study provides the first systematic map of drug-gene interactions in psychosis.
• Identified bridge genes and pathways offer novel insights into antipsychotic mechanisms.
• Haloperidol's unique drug-gene interaction profile suggests a distinct therapeutic action in schizophrenia.